Clinical Trial

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-02-17; most recent amendment 2026-03-17.
Status change: Not Yet Recruiting → Recruiting 2023-06-01
Trial Details
NCT Number NCT05748834
Lead Sponsor SCRI Development Innovations, LLC
Collaborators: Seagen Inc., Pfizer
Conditions Breast Cancer
Enrollment 36 participants
Start Date 2023-07-24
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-20